A new urine test to detect bladder cancer recurrence
Multiplex and multi-omic diagnostic test for bladder cancer recurrence
This study is testing a new, easy urine test called BCDx that uses advanced technology to check for signs of bladder cancer without needing any invasive procedures, making it a friendlier option for patients who need to monitor their condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Early Is Good INC. NIH-funded |
| Lab location | 1 site (Muncie, United States) |
| Project ID | NIH-10918479 on NIH RePORTER |
What this research studies
This research focuses on developing a diagnostic test called BCDx that uses advanced nanotechnology to analyze urine samples for multiple biomarkers associated with bladder cancer. Unlike current methods that require invasive procedures, this test aims to provide a non-invasive and highly accurate way to monitor for cancer recurrence. By measuring various types of biological molecules, including proteins and RNA, the test seeks to improve the sensitivity and specificity of bladder cancer detection. This innovative approach could lead to earlier treatment interventions and better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been diagnosed with bladder cancer and are at risk for recurrence.
Not a fit: Patients who have not been diagnosed with bladder cancer or those with other unrelated medical conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the need for invasive procedures and improve the accuracy of bladder cancer recurrence detection.
How similar studies have performed: Previous research has shown promise in using multi-omic approaches for cancer diagnostics, indicating potential success for this novel method.
Where this research is happening
Muncie, United States
- Early Is Good INC. — Muncie, United States (Active)
Researchers
- Principal investigator: Liyanage, Thakshila — Early Is Good INC.
- Study coordinator: Liyanage, Thakshila
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.